Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma

Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma

The multi-kinase inhibitor sorafenib is a primary treatment modality for advanced-stage hepatocellular carcinoma (HCC). However, the therapeutic benefits are short-lived due to innate and acquired resistance. Here, we examined how HCC cells respond to sorafenib and adapt to continuous and prolonged...

Full description

Bibliographic Details
Main Authors: Shusil K. Pandit, Giada Sandrini, Jessica Merulla, Valentina Nobili, Xin Wang, Alessia Zangari, Andrea Rinaldi, Dheeraj Shinde, Giuseppina M. Carbone, Carlo V. Catapano
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
liver cancer
hepatocellular carcinoma
sorafenib
tyrosine kinase inhibitors
drug resistance
mitochondria
Online Access:https://www.mdpi.com/2072-6694/13/23/6029

Internet

https://www.mdpi.com/2072-6694/13/23/6029

Similar Items